194 related articles for article (PubMed ID: 30949705)
1. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
Bhavnani SM; Zhang L; Hammel JP; Rubino CM; Bader JC; Sader HS; Gelone SP; Wicha WW; Ambrose PG
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae.
Wicha WW; Strickmann DB; Paukner S
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii11-iii18. PubMed ID: 30949707
[TBL] [Abstract][Full Text] [Related]
3. Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin.
Rodvold KA
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii2-iii4. PubMed ID: 30949709
[TBL] [Abstract][Full Text] [Related]
4. Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods.
Zhang L; Wicha WW; Bhavnani SM; Rubino CM
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii27-iii34. PubMed ID: 30949708
[TBL] [Abstract][Full Text] [Related]
5. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA
Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing.
Wicha WW; Prince WT; Lell C; Heilmayer W; Gelone SP
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii19-iii26. PubMed ID: 30949704
[TBL] [Abstract][Full Text] [Related]
7. Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections.
van Os W; Zeitlinger M
J Antimicrob Chemother; 2024 Feb; 79(2):443-446. PubMed ID: 38174805
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae.
Bhavnani SM; Hammel JP; Lakota EA; Trang M; Bader JC; Bulik CC; VanScoy BD; Rubino CM; Huband MD; Friedrich L; Steenbergen JN; Ambrose PG
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0221321. PubMed ID: 36946741
[TBL] [Abstract][Full Text] [Related]
9. In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model.
Wicha WW; Craig WA; Andes D
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii5-iii10. PubMed ID: 30949706
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
File TM; Goldberg L; Das A; Sweeney C; Saviski J; Gelone SP; Seltzer E; Paukner S; Wicha WW; Talbot GH; Gasink LB
Clin Infect Dis; 2019 Nov; 69(11):1856-1867. PubMed ID: 30722059
[TBL] [Abstract][Full Text] [Related]
11. Lefamulin: The First Systemic Pleuromutilin Antibiotic.
Chahine EB; Sucher AJ
Ann Pharmacother; 2020 Dec; 54(12):1203-1214. PubMed ID: 32493034
[TBL] [Abstract][Full Text] [Related]
12. Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
Paukner S; Goldberg L; Alexander E; Das AF; Heinrich S; Patel P; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Schranz J
J Glob Antimicrob Resist; 2022 Jun; 29():434-443. PubMed ID: 34788694
[TBL] [Abstract][Full Text] [Related]
13. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
File TM; Alexander E; Goldberg L; Das AF; Sandrock C; Paukner S; Moran GJ
BMC Pulm Med; 2021 May; 21(1):154. PubMed ID: 33964925
[TBL] [Abstract][Full Text] [Related]
14. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.
Veve MP; Wagner JL
Pharmacotherapy; 2018 Sep; 38(9):935-946. PubMed ID: 30019769
[TBL] [Abstract][Full Text] [Related]
15. Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia.
Lee YR; Jacobs KL
Drugs; 2019 Nov; 79(17):1867-1876. PubMed ID: 31705486
[TBL] [Abstract][Full Text] [Related]
16. Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.
Tang HJ; Wang JH; Lai CC
Medicine (Baltimore); 2020 Jul; 99(29):e21223. PubMed ID: 32702892
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).
Paukner S; Gelone SP; Arends SJR; Flamm RK; Sader HS
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670415
[TBL] [Abstract][Full Text] [Related]
18. 7-Year (2015-21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms.
Paukner S; Mendes RE; Arends SJR; Gassner G; Gelone SP; Sader HS
J Antimicrob Chemother; 2024 Feb; 79(2):360-369. PubMed ID: 38113528
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
Lepak AJ; Zhao M; Liu Q; Wang P; Wang Y; Bader JC; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
